全部

1·And the degree of hepatocyte steatosis did not change in the treatment group.

治疗组肝细胞脂肪变性程度无显著变化。

2·Moderate and heavy hepatic steatosis can be used in the liver transplantation.

中到重度小泡性肝细胞脂肪变是可用的。

3·The authors note that NAFLD was the most common cause (81.5%) of hepatic steatosis on ultrasound.

作者认为NAFLD是超声扫描下肝脏脂肪变性最常见的致病因素（81.5%）。

4·Moreover, it has been shown to induce steatosis, modulate apoptosis, and increase cellular oncogenic potential.

更且，它会引起脂肪变性，调节细胞凋亡，增加细胞的致癌性。

5·Conclusion: liver steatosis can result in narrow and irregular liver sinus and increase the portal vein pressure.

结论：肝脂肪变性引起肝窦狭窄和不规则，门脉压增高。

6·A few patients with simple steatosis may progress but the majority of them will not progress in terms of their liver disease.

而单纯脂肪变性的患者仅有一小部分会进展，而绝大多数不会发生肝病进展。

7·Conclusion: NHBT is an important risk factor leading to IPGF while steatosis in donor liver. CIT and RWIT are potential risk factors.

结论：NHBT延长是引起IPGF的主要危险因素，供肝脂肪变性、CIT、RWIT延长可能是潜在危险因素。

8·In cases like that where there is hepatic steatosis, actually treating the lipid can also have a favorable effect on the liver enzymes.

在这些存在脂肪肝的患者中，治疗高脂血症能够对肝酶产生有益的影响。

9·Increased triglyceride release and hepatic steatosis are the common features of hepatic insulin resistance, which deeply associated with increased FOXO1 transcription.

肝脏胰岛素抵抗还表现为脂代谢异常，如甘油三酯释放增加和肝脏脂肪变性，这与FOXO1转录活性增加有密切关系。

10·Understanding the molecule mechanisms of HCV core protein induction hepatic steatosis may contribute to elucidate the etiology, prevention and treatment of HCV hepatic diseases.

了解h CV核心蛋白在诱发肝脂肪变性中的分子学机制，对丙型肝炎相关性脂肪肝的病因学，预防和治疗等方面具有极大的促进作用。

脂肪变性

1·Moreover, it has been shown to induce steatosis, modulate apoptosis, and increase cellular oncogenic potential.

更且，它会引起脂肪变性，调节细胞凋亡，增加细胞的致癌性。

2·Potential adverse effects include peripheral neuropathy, myopathy, lactic acidosis and severe hepatomegaly with steatosis, and - after the stopping treatment - worsening of hepatitis.

潜在的不良反应包括周围神经病变，肌病，乳酸性酸中毒和严重的肝肿大伴脂肪变性，以及-停止治疗后-肝炎恶化。